![]() With advances in technology, it is now possible to analyze the genetic material of circulating tumor cells (CTCs) at the single cell level to evaluate spatial and temporal dynamics in circulation. In principle, liquid biopsy has the potential to reflect all subclones present at a specific point in time and enable sequential, longitudinal monitoring of a tumor’s evolutionary dynamics. Liquid biopsies offer a minimally invasive alternative, enabling analysis of tumor cells or tumor cell products that have been shed into bodily fluids. Tissue biopsy samples are commonly used for tumor characterization but are limited by sampling bias and constraints on sampling frequency. Making the Case for Liquid Biopsy Companion Diagnostics In this article, we discuss the utility of liquid biopsy in cancer genomics as well as a novel, next-generation sequencing (NGS) initiative designed to support and accelerate liquid biopsy-based diagnostics for precision oncology. ![]() The discovery and development of relevant biomarkers is a prerequisite to fulfillment of the promise of precision oncology, but the challenge for researchers is that clinically actionable mutations occur at very low frequency and sourcing biospecimens with specific mutations is extraordinarily difficult. ![]() Precision oncology leverages molecular information about cancer to personalize therapy and improve outcomes.
0 Comments
Leave a Reply. |